Filing Flows › Companies › AbCellera Biologics › Report card
AbCellera Biologics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 4 reports beat the EPS estimate
AbCellera Biologics (ABCL) beat the analysts' EPS estimate in 2 of its last 4 reports (50%), by +21.5% on average. On report days the stock moved 7.2% in either direction on median (largest 16.6%), rising 50% of the time. Next report: Nov 9, 2026, analysts expect EPS −$0.18.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.17 | −$0.18 | -9.1% | −$0.18 | $4.0M | +7.2% | +7.6% |
| Q1 2026 | May 11, 2026 | −$0.20 | −$0.14 | +29.1% | −$0.14 | $8.3M | -5.5% | -5.6% |
| Q4 2025 | Feb 24, 2026 | −$0.18 | −$0.03 | +83.3% | — | $44.9M | +5.3% | +3.7% |
| Q3 2025 | Nov 6, 2025 | −$0.16 | −$0.19 | -17.3% | −$0.19 | $9.0M | -16.6% | -15.7% |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 4 reports the stock moved 7.2% on median on the day (close to close), the largest move 16.6%.
The next report: what to expect → AbCellera Biologics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.